Mirum Pharmaceuticals’ Ctexli (chenodiol) has gained US Food and Drug Administration (FDA) approval for treating adults with cerebrotendinous xanthomatosis (CTX), a rare lipid storage disease. It is ...

The US Food and Drug Administration (FDA) late Friday revealed it has approved Ctexli (chenodiol) for the treatment of cerebrotendinous xanthomatosis (CTX) in adults. Developed by Mirum ...

Though it’s been used off-label for more than three decades to treat cerebrotendinous xanthomatosis, Mirum Pharmaceuticals Inc.’s chenodiol gained an official U.S. FDA nod Feb. 21 as the first drug ...

The Food and Drug Administration has approved Ctexli (chenodiol) for the treatment of cerebrotendinous xanthomatosis in adults.

Ctexli’s approval further entrenches Mirum as a leader in rare liver diseases, alongside its cornerstone product Livmarli and ...

US Food and Drug Administration (FDA) has approved Ctexli (chenodiol) tablets, a bile acid, for the treatment of adults with cerebrotendinous xanthomatosis (CTX). Ctexli is the first and only ...

Feb. 21, 2025 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Ctexli (chenodiol) for the treatment of cerebrotendinous xanthomatosis (CTX) in adults. Ctexli is the first FDA ...

Ctexli 250mg 3 times daily showed significant reductions in plasma cholestanol and urine 23S-pentol compared with placebo. The Food and Drug Administration (FDA) has approved Ctexli ™ (chenodiol ...

“Cerebrotendinous xanthomatosis (CTX) is a rare disease that can present with early cataracts, tendon lipid deposits, and significant neurologic disease, and the latter may be prevented with ...